Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Melanoma

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 44 articles:
HTML format

Single Articles

    March 2023

  1. Erratum: COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
    J Clin Oncol. 2023 Mar 8:JCO2300385. doi: 10.1200/JCO.23.00385.

    February 2023
  2. DEVLIN O, Oladipo O
    Sequencing of Targeted Treatment and Immunotherapy in Advanced BRAF-Mutant Melanoma.
    J Clin Oncol. 2023 Feb 15:JCO2202250. doi: 10.1200/JCO.22.02250.

  3. ASCIERTO PA, Lipson EJ, Dummer R, Larkin J, et al
    Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
    J Clin Oncol. 2023 Feb 13:JCO2202072. doi: 10.1200/JCO.22.02072.
    PubMed     Abstract available

  4. TOPALIAN SL, Sznol M, McDermott DF, Kluger HM, et al
    Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
    J Clin Oncol. 2023;41:943-954.
    PubMed     Abstract available

    Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term Safety.
    J Clin Oncol. 2023;41:941-942.

    January 2023
  6. KIRKWOOD JM, Strawderman MH, Ernstoff MS, Smith TJ, et al
    Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.
    J Clin Oncol. 2023;41:425-435.
    PubMed     Abstract available

    Flashback Foreword: Adjuvant Interferon alpha-2b for High-Risk Melanoma.
    J Clin Oncol. 2023;41:423-424.

    December 2022
    Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases.
    J Clin Oncol. 2022 Dec 1:JCO2201903. doi: 10.1200/JCO.22.01903.

    Risk of Overusing Sentinel Node Biopsy in Patients With Thin Melanoma.
    J Clin Oncol. 2022 Dec 1:JCO2201963. doi: 10.1200/JCO.22.01963.

    November 2022
  10. BOUFFET E, Geoerger B, Moertel C, Whitlock JA, et al
    Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.
    J Clin Oncol. 2022 Nov 14:JCO2201000. doi: 10.1200/JCO.22.01000.
    PubMed     Abstract available

    September 2022
  11. ATKINS MB, Lee SJ, Chmielowski B, Tarhini AA, et al
    Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial - ECOG-ACRIN EA6134.
    J Clin Oncol. 2022 Sep 27:101200JCO2201763. doi: 10.1200/JCO.22.01763.
    PubMed     Abstract available

  12. WEBER JS, Schadendorf D, Del Vecchio M, Larkin J, et al
    Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
    J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533.
    PubMed     Abstract available

  13. AUGUSTIN RC, Luke JJ
    Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma.
    J Clin Oncol. 2022 Sep 26:JCO2201770. doi: 10.1200/JCO.22.01770.

  14. CHANDRA S, Choi JS, Sosman JA
    Melanoma: Does Sequencing Really Matter?
    J Clin Oncol. 2022 Sep 20:JCO2201354. doi: 10.1200/JCO.22.01354.

  15. ASCIERTO PA, Mandala M, Ferrucci PF, Guidoboni M, et al
    Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
    J Clin Oncol. 2022 Sep 1:JCO2102961. doi: 10.1200/JCO.21.02961.
    PubMed     Abstract available

    August 2022
  16. CHESNEY JA, Ribas A, Long GV, Kirkwood JM, et al
    Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
    J Clin Oncol. 2022 Aug 23:JCO2200343. doi: 10.1200/JCO.22.00343.
    PubMed     Abstract available

    July 2022
  17. ARANCE A, de la Cruz-Merino L, Petrella TM, Jamal R, et al
    Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
    J Clin Oncol. 2022 Jul 22:JCO2200221. doi: 10.1200/JCO.22.00221.
    PubMed     Abstract available

  18. DUMMER R, Flaherty KT, Robert C, Arance A, et al
    COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
    J Clin Oncol. 2022 Jul 21:JCO2102659. doi: 10.1200/JCO.21.02659.
    PubMed     Abstract available

    What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma?
    J Clin Oncol. 2022 Jul 21:JCO2201066. doi: 10.1200/JCO.22.01066.

  20. MONCRIEFF MD, Lo SN, Scolyer RA, Heaton MJ, et al
    Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
    J Clin Oncol. 2022 Jul 18:JCO2102488. doi: 10.1200/JCO.21.02488.
    PubMed     Abstract available

    June 2022
  21. GARBE C, Keim U, Amaral T, Berking C, et al
    Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
    J Clin Oncol. 2022 Jun 16:JCO2200202. doi: 10.1200/JCO.22.00202.
    PubMed     Abstract available

  22. SETH R, Messersmith H, Funchain P
    Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Jun 3:JCO2200944. doi: 10.1200/JCO.22.00944.
    PubMed     Abstract available

    March 2022
  23. OLIVIER T, Prasad V
    Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial.
    J Clin Oncol. 2022 Mar 8:JCO2102904. doi: 10.1200/JCO.21.02904.

  24. CARVAJAL RD, Nathan P, Sacco JJ, Orloff M, et al
    Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
    J Clin Oncol. 2022 Mar 7:JCO2101805. doi: 10.1200/JCO.21.01805.
    PubMed     Abstract available

    February 2022
  25. PIRES DA SILVA I, Ahmed T, McQuade JL, Nebhan CA, et al
    Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
    J Clin Oncol. 2022 Feb 10:JCO2101701. doi: 10.1200/JCO.21.01701.
    PubMed     Abstract available

    January 2022
  26. CALLAHAN MK, Chapman PB
    PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2102801. doi: 10.1200/JCO.21.02801.

  27. DUMMER R, Long GV, Robert C, Tawbi HA, et al
    Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2101601. doi: 10.1200/JCO.21.01601.
    PubMed     Abstract available

    December 2021
  28. POSTOW MA, Goldman DA, Shoushtari AN, Betof Warner A, et al
    Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
    J Clin Oncol. 2021 Dec 20:JCO2101570. doi: 10.1200/JCO.21.01570.
    PubMed     Abstract available

    November 2021
  29. WOLCHOK JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al
    Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    J Clin Oncol. 2021 Nov 24:JCO2102229. doi: 10.1200/JCO.21.02229.
    PubMed     Abstract available

    August 2021
  30. ANDTBACKA RHI, Curti B, Daniels GA, Hallmeyer S, et al
    Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
    J Clin Oncol. 2021 Aug 31:JCO2003246. doi: 10.1200/JCO.20.03246.
    PubMed     Abstract available

    July 2021
  31. DIAB A, Tykodi SS, Daniels GA, Maio M, et al
    Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
    J Clin Oncol. 2021 Jul 13:JCO2100675. doi: 10.1200/JCO.21.00675.
    PubMed     Abstract available

    June 2021
  32. HUPPERT LA, Daud AI
    Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma.
    J Clin Oncol. 2021 Jun 17:JCO2100943. doi: 10.1200/JCO.21.00943.

    Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.
    J Clin Oncol. 2021 Jun 4:JCO2101012. doi: 10.1200/JCO.21.01012.

    May 2021
  34. SARNAIK AA, Hamid O, Khushalani NI, Lewis KD, et al
    Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
    J Clin Oncol. 2021 May 12:JCO2100612. doi: 10.1200/JCO.21.00612.
    PubMed     Abstract available

  35. OLSON DJ, Eroglu Z, Brockstein B, Poklepovic AS, et al
    Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
    J Clin Oncol. 2021 May 4:JCO2100079. doi: 10.1200/JCO.21.00079.
    PubMed     Abstract available

    February 2021
  36. EL SHAROUNI MA, Ahmed T, Varey AHR, Elias SG, et al
    Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.
    J Clin Oncol. 2021 Feb 18:JCO2002446. doi: 10.1200/JCO.20.02446.
    PubMed     Abstract available

    January 2021
    Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003523. doi: 10.1200/JCO.20.03523.

  38. HINDIE E
    Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003213. doi: 10.1200/JCO.20.03213.

  39. YAN X, Sheng X, Chi Z, Si L, et al
    Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 14:JCO2000902. doi: 10.1200/JCO.20.00902.
    PubMed     Abstract available

  40. PIULATS JM, Espinosa E, de la Cruz Merino L, Varela M, et al
    Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    J Clin Oncol. 2021 Jan 8:JCO2000550. doi: 10.1200/JCO.20.00550.
    PubMed     Abstract available

  41. KHAN S, Carvajal RD
    Dual Immunological Checkpoint Blockade for Uveal Melanoma.
    J Clin Oncol. 2021 Jan 8:JCO2003274. doi: 10.1200/JCO.20.03274.

    October 2020
  42. PELSTER MS, Gruschkus SK, Bassett R, Gombos DS, et al
    Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    J Clin Oncol. 2020 Oct 30:JCO2000605. doi: 10.1200/JCO.20.00605.
    PubMed     Abstract available

    September 2020
  43. ROBERT C, Long GV, Brady B, Dutriaux C, et al
    Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
    J Clin Oncol. 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995.
    PubMed     Abstract available

    April 2020
  44. TAYLOR MH, Lee CH, Makker V, Rasco D, et al
    Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    J Clin Oncol. 2020;38:1154-1163.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.